Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (Q30278902)

11 August 2017

Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer (English)

1 reference

11 August 2017

1 reference

Nicholas J. Vogelzang

12

object named as

Nicholas J Vogelzang

1 reference

11 August 2017

3

Michael Carducci

1 reference

11 August 2017

Christopher J Sweeney

1

1 reference

11 August 2017

Yu-Hui Chen

2

1 reference

11 August 2017

Glenn Liu

4

1 reference

11 August 2017

David F Jarrard

5

1 reference

11 August 2017

Mario Eisenberger

6

1 reference

11 August 2017

Yu-Ning Wong

7

1 reference

11 August 2017

Noah Hahn

8

1 reference

11 August 2017

Manish Kohli

9

1 reference

11 August 2017

Matthew M Cooney

10

1 reference

11 August 2017

Robert Dreicer

11

1 reference

11 August 2017

Joel Picus

13

1 reference

11 August 2017

Daniel Shevrin

14

1 reference

11 August 2017

Maha Hussain

15

1 reference

11 August 2017

Jorge A Garcia

16

1 reference

11 August 2017

Robert S DiPaola

17

1 reference

11 August 2017

language of work or name

English

0 references

publication date

5 August 2015

1 reference

The New England Journal of Medicine

11 August 2017

1 reference

11 August 2017

373

1 reference

11 August 2017

8

1 reference

11 August 2017

737-746

1 reference

Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).

11 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Enzalutamide in metastatic prostate cancer before chemotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Alpha emitter radium-223 and survival in metastatic prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Intermittent versus continuous androgen deprivation in prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Abiraterone in metastatic prostate cancer without previous chemotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346).

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Increased survival with enzalutamide in prostate cancer after chemotherapy

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Abiraterone and increased survival in metastatic prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Phase III trial of androgen ablation with or without three cycles of systemic chemotherapy for advanced prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Evaluation of survival data and two new rank order statistics arising in its consideration

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4562797

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26244877

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26244877

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1056/NEJMOA1503747

1 reference

11 August 2017

1 reference

11 August 2017

PubMed publication ID

26244877

1 reference